Major immunotherapy trial sees survival benefit in solid tumours
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
List view / Grid view
News
Innovative static culturing method developed
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.
Single-use bioreactor market to witness favourable expansion to 2030
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
First-of-a-kind EU approval granted for eosinophilic esophagitis medicine
With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.
Encouraging data revealed for schizophrenia long-acting injectables
Key Phase III and real-world data highlight potential advancements in long-acting injectable treatment options for schizophrenia, Teva and Medincell share.
Final Chapter <86> text published for early adoption
The Chapter for endotoxin testing using non-animal derived reagents will help quality professionals ensure the safety of sterile pharmaceutical products.
Sustainability continues to steer pharmaceutical packaging market
Europe’s emphasis on sustainability combined with its established infrastructure to support market growth, means the region is leading the pharmaceutical containers market, with potential to hold this position into the next decade, research anticipates.
Standout breast cancer trial outcomes for Roche small molecule therapy
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
Novel nanoemulsion-based delivery of antimycobacterial drug
The manufacturing process for the nanoemulsion could be adapted for industrial-scale production, the researchers suggested.
AbbVie agrees $1.4 billion Alzheimer’s acquisition
The deal will help AbbVie to strengthen its neuroscience pipeline, including supporting development of next-generation therapies for delivery into the central nervous system.
ACG 2024: J&J data reveals new Crohn’s treatment option
More patients given subcutaneous induction and maintenance treatment with Johnson & Johnson’s biologic obtained clinical remission at 48 weeks, compared to placebo, Phase III data showed.
Trial highlights potential next-gen biologic for lung cancer
Preliminary results from an ongoing trial of a novel monoclonal antibody have confirmed favourable efficacy and safety in recurrent extensive-stage small cell lung cancer (SCLC).
Optimising drug release of personalised 3D printed tablets
The 3D printing study enabled a precise tablet structure to be created, allowing for easy modification and for the control of drug release rate through changing the surface curvature.
Eli Lilly secures MHRA authorisation for Alzheimer’s treatment
Authorisation in Great Britain means eligible Alzheimer's patients can access the treatment, which is part of a new class of amyloid targeting therapies.
World-first medicine manufacturing regulatory framework to be implemented
The new regulation could become lawful in the UK next year, according to the Medicines and Healthcare products Regulatory Agency (MHRA).
